The FDA’s Antiviral Drugs Advisory Committee voted 15 – 0 to recommend approval of Gilead Sciences Inc.’s sofosbuvir for genotype 2 and 3 hepatitis C virus (HCV) patients and for treatment-naïve genotype 1 and 4 patients.